Politics
United Nations Removes Marijuana From Most Strict Global Drug Category, With U.S. Support
A key United Nations (UN) panel approved a World Health Organization (WHO) recommendation to remove marijuana from the most restrictive global scheduling category on Wednesday.
With the backing of the U.S. government, the UN’s Commission on Narcotic Drugs (CND) adopted the proposal to delete cannabis from Schedule IV of the 1961 Single Convention.
This doesn’t mean that member nations are cleared to legalize marijuana, however, as it remains under the separate Schedule I of the international drug control system. But advocates say it demonstrates an evolution in how the international community views cannabis policy, as it formally recognizes the medical value of the plant and it could promote further research into its therapeutic potential.
WHO made six recommendations on global cannabis policy last year—and CND has held numerous meetings on the proposals. After numerous meetings and delays, members finally held votes at a meeting this week.
The proposal to remove marijuana from Schedule IV was arguably the most consequential of the reforms, and is the only one that was approved. (The international scheduling system differs from that of the U.S. in that the country’s most restrictive category is Schedule I.)
Here’s a rundown of the votes on the WHO’s cannabis recommendations:
APPROVED: Remove marijuana from Schedule IV of the 1961 Single Convention.
REJECTED: Add THC and dronabinol (synthetic or plant-derived THC medication) to Schedule I of the 1961 Convention and, if approved, delete them from Schedule II of the 1971 Convention.
REJECTED: If the second recommendation is adopted, add tetrahydrocannabinol to Schedule I of the 1961 Convention and, if approved, delete it from Schedule I of the 1971 Convention.
REJECTED: Delete “extracts and tinctures of cannabis” from Schedule I of the 1961 Convention.
REJECTED: Add footnote to clarify that CBD products containing no more than 0.2 percent THC are not subject to international control.
REJECTED: Add “preparations containing dronabinol” to Schedule III of the 1961 Convention.
The vote to move cannabis out of its restrictive scheduling status was close, with 27 countries in favor, 25 against and one abstention.
“The vote of the United States to remove cannabis and cannabis resin from Schedule IV of the Single Convention while retaining them in Schedule I is consistent with the science demonstrating that while a safe and effective cannabis-derived therapeutic has been developed, cannabis itself continues to pose significant risks to public health and should continue to be controlled under the international drug control conventions,” the U.S. delegation said in a statement.
“Further, this action has the potential to stimulate global research into the therapeutic potential and public health effects of cannabis, and to attract additional investigators to the field, including those who may have been deterred by the Schedule IV status of cannabis,” the country added.
#EU supports successful vote at @CND_tweets to recognise potential therapeutic value of #cannabis
Read here the full Explanation of #CND vote on @WHO scheduling recommendations on cannabis and cannabis-related substances:
https://t.co/lNAG9WaM6M pic.twitter.com/VrdiHYCLCw— EU Delegation Vienna 🇪🇺 (@euunvie) December 2, 2020
Russia, China and Pakistan were among those nations that opposed the reform.
🇷🇺Russia voted against all @WHO/ECDD recommendations on cannabis and cannabis-related substances. Half of the CND membership shares the same position. pic.twitter.com/Ep8m1gfnxt
— Russian Mission Vienna (@mission_rf) December 2, 2020
Advocates cheered the move while saying it doesn’t go far enough.
“After six decades since its placement into the strictest international category, and three years of review, the UN has finally made the decision to recognize the therapeutic value of cannabis,” Steph Sherer, president and founder of Americans for Safe Access and the International Medical Cannabis Patients Coalition, said in a press release. “This is a momentous occasion for cannabis advocates everywhere who have been fighting for this change for many years.
Ann Fordham, executive director of the International Drug Policy Consortium, welcomed the “long overdue recognition that cannabis is a medicine” from the international body.
“However, this reform alone is far from adequate given that cannabis remains incorrectly scheduled at the international level,” she said. “The original decision to prohibit cannabis lacked scientific basis and was rooted in colonial prejudice and racism. It disregarded the rights and traditions of communities that have been growing and using cannabis for medicinal, therapeutic, religious and cultural purposes for centuries and has led to millions being criminalized and incarcerated across the globe. The review process has been a missed opportunity to correct that historical error.”
Here's how the 53 member states in the Commission on Narcotic Drugs voted on the WHO recommendation to remove cannabis from Schedule IV of the 1961 single convention – finally acknowledging its medicinal and therapeutic utility
HT @jfernandezochoa @IDPCAsia pic.twitter.com/26lTMSpFdX
— TransformDrugPolicy (@TransformDrugs) December 2, 2020
The U.S. said in October that it would be supporting the WHO recommendation to remove cannabis from the restrictive global drug scheduling category—though it was opposing the other cannabis reform proposals, including the one to clarify that CBD is not under international control.
Despite supporting the main scheduling recommendation, however, the country circulated a proposed joint statement to other member states that claimed consensus on the notion “that cannabis is properly subject to the full scope of international controls of the 1961 Single Convention, due in particular to the high rates of public health problems arising from cannabis use and the global extent of such problems, as identified in the critical review by WHO.”
It also stipulates that “no Party shall be precluded from adopting measures of control more strict or severe than those required as a result of this decision, if such measures in its opinion are necessary or desirable for the protection of the public health or welfare.” The language seems to attempt to leave room for countries to continue enforcing more restrictive cannabis policies regardless of international rules.
While the WHO’s CBD recommendation would simply offer clarification that cannabidiol products containing no more than 0.2 percent THC isn’t a controlled substance under international treaties, the U.S. and the vast majority of other countries voted against the measure.
“This recommendation to give effect to a state of affairs which already exists therefore breaks from past procedure and intrudes on the treaty-based mandate of the CND to make recommendations for the implementation of the aims and provisions of the drug control conventions,” the U.S. said in explaining its vote. “Additionally, adoption of the proposed footnote would have in effect amended the Single Convention by creating a new category of preparations wholly excluded from control.”
“The treaties give significant flexibility to allow Member States to design drug control polices that reflect their national realities,” the country added. “We believe the Member States are capable of determining for themselves what should be considered a ‘pure’ cannabidiol preparation for domestic enforcement purposes, based on analytical capacity, abuse liability, and prioritization of prosecutorial resources.”
The U.S.’s support for the separate recommendation to remove marijuana from Schedule IV represents a departure from its position as articulated in a government document that Marijuana Moment obtained earlier this year. The document stated that it’s “possible that civil society, the media, and the general public will view deleting cannabis from Schedule IV as a first step toward widespread legalization of marijuana use, especially without proper messaging.”
If the recommendation on CBD had been adopted, it could have had far-reaching implications in the U.S. In 2018, the FDA determined that CBD does not meet the criteria for federal control—except for the fact that international treaties to which the U.S. is party could potentially be construed as requiring it.
FDA has on several occasions solicited public input to shape the government’s position on the international scheduling of marijuana and cannabinoids. The agency initially requested feedback on the proposal in March 2019 and then reopened that comment period five months later.
GOP Lawmakers Slam Marijuana Legalization Vote Planned In Congress This Week
Photo courtesy of Mike Latimer.
Politics
State Treasurers Discuss Marijuana Banking Challenges At Annual Conference With Congressional Officials
State treasures from across the U.S. participated in a panel on Tuesday that focused on federal marijuana banking reform as part of a three-day conference organized by the National Association of State Treasurers (NAST) that was attended by stakeholders and congressional officials.
Moderated by Colorado Treasurer Dave Young, the panel discussed the “history, challenges, and prospects for SAFE banking laws that would allow legal cannabis businesses into the mainstream banking system,” according to an event description.
My pleasure! Let’s pass the #SAFEBankingAct in the Senate! https://t.co/2L9qcHhsZG
— Colorado Treasurer Dave Young (@ColoTreasurer) March 15, 2022
The Secure and Fair Enforcement (SAFE) Banking Act was a focal point of the discussion. That bill, sponsored by Rep. Ed Perlmutter (D-CO), would protect financial institutions that choose to service state-legal cannabis businesses from being penalized by federal regulators. It’s passed the U.S. House of Representatives in some form six times but has yet to advance in the Senate under either Republican or Democratic control.
Perlmutter’s senior legislative assistant Colin Anonsen spoke on the NAST conference panel, alongside representatives of Scotts Miracle-Gro and the American Bankers Association (ABA).
ABA recently released a poll it commissioned showing majority support for marijuana banking reform among Americans.
State treasurers have been among the consistent voices pushing Congress to take action on the issue, submitting multiple letters to leadership on the issue over the years, for example. In 2019, NAST adopted a resolution endorsing “common sense federal laws and regulations to provide essential banking services to state legalized cannabis businesses.”
—
Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—
“NAST supports common sense federal laws and regulations to provide essential banking services to state legalized cannabis businesses, promote public safety and financial transparency, and facilitate local, state, and federal tax and fee collection without compromising federal enforcement of anti-money laundering laws against criminal enterprises,” the organization said in a statement to Marijuana Moment.
However, a spokesperson emphasized that NAST “takes no position as to whether cannabis should be legalized under the laws of the United States or of any state.”
On the first day of the NAST conference on Sunday, members of the organization’s Banking and Cash Management Committee also met to discuss the organization’s previously adopted banking resolution, which is due to be renewed this year. Washington State Treasurer Mike Pellicciotti serves as a member of that committee and told Marijuana Moment in a statement that he’s “committed to doing everything my office can do to urge Congress to legalize cannabis banking this year.”
In DC, affirming support for banking reform for the cannabis industry. “As the first state with legal #cannabis a decade ago, WA must convince #congress to finally get our state’s legal #marijuana retail stores out of the cash business an into banking.”
– Treasurer Pellicciotti— WA State Treasurer (@WaTreasurer) March 14, 2022
“Legal retailers must be allowed out of the cash business to stop the inequities and traumatic daily robberies taking place in Washington state and around the country due to a decade of congressional inaction,” he said. “I’m focused on uniting state treasurers around the country to amplify this critical equity and public safety issue in America, and I look forward to meeting with members of Congress this week to explain why it must pass cannabis banking now.”
While he is in D.C., Pellicciotti plans to meet with lawmakers to discuss cannabis banking and other issues of interest.
In the House, Perlmutter has been vocal about his frustration over inaction on his SAFE Banking Act in the Senate. He has also continued to raise the issue in committee hearings, even those that don’t necessarily pertain to the issue.
At a recent event hosted by ABA, the congressman promised to “continue to be a real pest, and persistent in getting this done” before he retires from Congress at the end of the session.
Following the bipartisan House passage of the banking bill, Perlmutter said he naively expected it “to sail through the Senate, which is always a bad assumption, because nothing sails through the Senate.”
But he’s taken pains to build support, including from current Senate leadership that has insisted on enacting comprehensive legalization with firm equity provisions in place before advancing a bill viewed as friendly to the industry.
Despite recently saying that he’s “confident” that the Senate will take up his bill this session, the congressman recognized that while he’s supportive of revisions related to criminal justice reform, taxation, research and other issues, he knows that “as we expand this thing, then we start losing votes, particularly Republican votes and we got enough votes in the Senate to do it” as is.
Perlmutter also brought up the fact that Treasury Secretary Janet Yellen has addressed the federal-state marijuana banking conflict and “she wants to get this off her plate and get it done.”
Meanwhile, the number of banks that report working with marijuana businesses ticked up again near the end of 2021, according to recently released federal data.
It’s not clear if the increase is related to congressional moves to pass a bipartisan cannabis banking reform bill, but the figures from the Financial Crimes Enforcement Network (FinCEN) signal that financial institutions continue to feel more comfortable servicing businesses in state-legal markets.
Some Republicans have questioned how Democrats have so far failed to pass the modest banking reform with majorities in both chambers and control of the White House, too. For example, Rep. Rand Paul (R-KY) criticized his Democratic colleagues over the issue in December.
In the interim, federal financial regulator Rodney Hood—a board member and former chairman of the federal National Credit Union Administration (NCUA)—recently said that marijuana legalization is not a question of “if” but “when,” and he’s again offering advice on how to navigate the federal-state conflict that has left many banks reluctant to work with cannabis businesses.
Colorado Activists Pick One Of Several Psychedelics Reform Initiatives To Pursue For November Ballot
Politics
Colorado Activists Pick One Of Several Psychedelics Reform Initiatives To Pursue For November Ballot
Colorado activists have made a decision: of the four psychedelics reform ballot initiatives that they drafted and filed for the November ballot, they will proceed with a measure to legalize psilocybin, create licensed “healing centers” where people can use the psychedelic for therapeutic purposes and provide a pathway for record sealing for prior convictions.
The proposal would also eventually allow regulators to decide whether to legalize DMT, ibogaine and mescaline.
The New Approach PAC-backed campaign went into this election season with several options. Colorado officials have given tentative approval to the ballot language of four psychedelics reform measures that they submitted—all titled the Natural Medicine Health Act—but it was always the plan to pursue only one version. Now they’ve requested permission from the state to start signature gathering for Initiative 58.
The campaign conducted internal polls on the differing provisions between the proposals to help inform their decision, and evidently advocates are confident that the public will back the measure if it ultimately makes the ballot.
Kevin Matthews, the campaign manager behind Denver’s historic 2019 vote to locally decriminalize psilocybin, and Veronica Perez are the designated representatives of these measures.
Matthews told Marijuana Moment that the campaign “chose Initiative 58 because it is our most comprehensive policy and it ensures that all Coloradans will have the option to access natural medicines in the way that makes sense for them.”
“We’re thrilled to hit the ground running in the next few weeks to engage voters and begin collecting signatures to appear on the ballot in November,” he said.
Rick Ridder of RBI Strategies, a spokesperson for the campaign, said that the initiative, once enacted, will help address widespread mental health issues.
“Many of us are, or know someone who is, struggling with depression, trauma, addiction, anxiety or other mental health issues. And during the pandemic, mental health challenges have only gotten worse,” he said.
“The Natural Medicine Health Act would create a state-regulated system for safe and supported access to natural medicine like psilocybin mushrooms,” he said. “Under the Act, adults 21 and older could access natural medicines that show promise in improving mental wellness while under the guidance of a licensed and trained facilitator at licensed healing centers, in the comfort and safety of their own home or in approved health care locations like palliative care facilities.”
While four psychedelics reform initiatives from the campaign were in play, advocates have already pulled the first two and plan to withdraw the third, No. 59, which shared most of the provisions included in No. 58.
Both 58 and 59 call for a two-tiered regulatory model, where only psilocybin would be legalized and regulated for therapeutic use until June 2026, after which point regulators could expand the policy change to include other psychedelics that are listed in the proposal.
The decision to add additional psychedelics to the program would be made by the Department of Regulatory Agencies in consultation with a Natural Medicine Advisory Board that would be established. The board would be comprised of 15 members, including people who have experience with psychedelic medicine in a scientific and religious context.
—
Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—
The key difference between the two is that one contains a component specifically authorizing people to petition courts for record sealing for past convictions that would be made legal under the proposal.
The group chose that initiative and is eager to begin signature gathering to try to qualify for the November ballot.
Under the proposal, the Department of Regulatory Agencies would be responsible for developing rules for a therapeutic psychedelics program where adults 21 and older could visit a licensed “healing center” to receive treatment under the guidance of a trained facilitator.
With respect to the initial two reform proposals that New Approach submitted before making the decision to pull them—Nos. 49 and 50—one would have legalized a wide range of entheogenic substances including DMT, ibogaine and mescaline, as well as establish a regulatory model for psychedelics therapy. The other would have initially enacted the reform for psilocybin and psilocin alone.
But recognizing that regulators would have been faced with an onerous task to set up rules for multiple psychedelics, they chose to revise them to create the two-tiered regulatory model with initial legalization of psilocybin alone while leaving it to regulators to potentially add more substances later.
There’s another complication in the push for statewide psychedelics reform in Colorado. A separate campaign headed by Decriminalize Nature Colorado, which has taken issue with the regulations prescribed in the New Approach-backed measures, filed a competing initiative in January that is also making its way through the process of being able to collect signatures.
Decriminalize Nature Colorado’s Nicole Foerster told Marijuana Moment that their group’s “initiative to decriminalize entheogenic plants and fungi in Colorado has made it through both the review/comment and title board hearings and is on track to begin petitioning this month.”
That one-page measure would allow adults 21 and older to possess, cultivate, gift and deliver psilocybin, psilocyn, ibogaine, mescaline and DMT.
Further, the measure says that it would be lawful to conduct psychedelics services for guidance, therapy and harm reduction and spiritual purposes with or without accepting payment. It would not be legal to sell any of the psychedelics, however.
Foerster said that the group believes “it is too soon to prioritize” setting up an infrastructure for regulated therapeutic access as in the New Approach reform proposal “without first ensuring full decriminalization has been achieved.”
“Decriminalization allows for communities to organize and for more research to occur that will direct how future policies look,” they said. “By proposing decriminalization and regulation at the same time, regulation is prioritized, and the crucial window of time between decriminalization and future policies is sealed shut.”
Asked to share their thoughts about apparent advocacy “infighting” over the proper route for psychedelics reform, Foerster argued that the term is misrepresentative “because it does not take into account the true power dynamics at play when out of state corporate interest seeks to dictate policy to local movements.”
In general, the Colorado ballot initiatives seek to accomplish something similar to what California activists are also actively pursuing with a proposed ballot initiative to legalize psilocybin mushrooms.
Meanwhile, legislative efforts to enact psychedelics reform are also underway in other states across the country.
For example, a Connecticut legislative committee on Monday discussed a bill that would set the state up to provide certain patients with access to psychedelic-assisted treatment with substances like MDMA and psilocybin. Former top military officials, advocates and scientists testified in favor of the proposal.
The Washington State legislature last week sent a budget bill to the governor’s desk that includes a proposal to direct $200,000 in funding to support a new workgroup to study the possibility of legalizing psilocybin services in the state, including the idea of using current marijuana regulatory systems to track psychedelic mushrooms.
Last week, the Hawaii Senate approved a bill to set up a state working group to study the therapeutic benefits of psilocybin mushrooms and develop a “long-term” plan to ensure that the psychedelic is accessible for medical use for adults 21 and older.
Also last week, the Oklahoma House of Representatives passed a bill this week to decriminalize low-level possession of psilocybin and promote research into the therapeutic potential of the psychedelic.
A bipartisan coalition of Georgia lawmakers recently filed a resolution that calls for the formation of a House study committee to investigate the therapeutic potential of psychedelics like psilocybin and make recommendations for reforms.
Rhode Island lawmakers introduced a pair of drug decriminalization bills this month—including one focused on psilocybin and buprenorphine that would authorize doctors to prescribe the psychedelic mushroom.
Also this month, a Missouri Republican lawmaker filed a bill that would legalize a wide range of psychedelics for therapeutic use at designated care facilities while further decriminalizing low-level possession in general.
Last month, Utah lawmakers sent a bill to the governor that would create a task force to study and make recommendations on the therapeutic potential of psychedelic drugs and possible regulations for their lawful use.
An Oregon Senate committee also recently advanced a bill to ensure that equity is built into the state’s historic therapeutic psilocybin program that’s actively being implemented following voter approval in 2020.
A group of Maryland senators recently filed a bill that would create a state fund that could be used to provide free access to psychedelics like psilocybin, MDMA and ketamine for military veterans suffering from post-traumatic stress disorder (PTSD), while also supporting research into their therapeutic potential.
A bill to decriminalize a wide array of psychedelics in Virginia was taken up by a House of Delegates panel in January, only to be pushed off until 2023. A separate Senate proposal to decriminalize psilocybin alone was later defeated in a key committee.
California Sen. Scott Wiener (D) told Marijuana Moment in a recent interview that his bill to legalize psychedelics possession stands a 50/50 chance of reaching the governor’s desk this year. It already cleared the full Senate and two Assembly committees during the first half of the two-year session.
Washington State lawmakers also introduced legislation in January that would legalize what the bill calls “supported psilocybin experiences” by adults 21 and older.
New Hampshire lawmakers filed measures to decriminalize psilocybin and all drugs.
Legislation was also enacted by the Texas legislature last year requiring the state to study the medical risks and benefits of psilocybin, MDMA and ketamine for military veterans in partnership with Baylor College of Medicine and a military-focused medical center.
Michigan activists filed a statewide ballot initiative last month that would legalize possessing, cultivating and sharing psychedelics and set up a system for their therapeutic and spiritual use.
A pair of Michigan senators also introduced a bill in September to legalize the possession, cultivation and delivery of an array of plant- and fungi-derived psychedelics like psilocybin and mescaline.
At the congressional level, bipartisan lawmakers sent a letter to the Drug Enforcement Administration (DEA) in January, urging that the agency allow terminally ill patients to use psilocybin as an investigational treatment without the fear of federal prosecution.
Connecticut Lawmakers Discuss Bill To Fund Psilocybin And MDMA Therapy
Politics
Key Pennsylvania Senate Committee Completes Final Marijuana Legalization Hearing To Inform Reform Legislation
A key Pennsylvania Senate committee on Monday held the last of three scheduled hearings on marijuana legalization, taking testimony that’s designed to help inform a forthcoming reform bill that the panel’s chairman is actively drafting.
The Senate Law and Justice Committee meeting involved testimony from cannabis reform advocates, former regulators from other states and industry stakeholders.
Sen. Mike Regan (R), who chairs the panel, circulated a cosponsorship memo last year along with Rep. Amen Brown (D) to build support for the reform, and these meetings are designed to give lawmakers added context into the best approach to legalization for the state.
“Legalization of adult-use marijuana is a complex and obviously controversial issue,” Regan said at the end of Monday’s discussion. “We are grateful for the many perspectives, personal experiences and opinions we have received. To all my colleagues on the committee, thank you for your continued participation. I look forward to working together on this important issue for Pennsylvania.”
At an initial hearing last month, much of the discussion focused on whether creating a regulated market would be sufficient to eliminate illicit sales, how police would be affected and the impact on impaired driving.
—
Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—
The second hearing held late last month centered on varying tax structures and other regulatory approaches that have been created in states like Illinois and California.
While reform bills have been introduced in past sessions and the policy change has the support of Gov. Tom Wolf (D), this latest hearing marks only the third time a legislative panel has debated recreational legalization in the Republican-controlled Pennsylvania General Assembly.
JM Pedini, development director of NORML and executive director of Virginia NORML, spoke about regulatory models and said that in their capacity as a member of the Virginia Governor’s Marijuana Task Force, “one of our principle tasks was recommending the form and function of the new regulatory structure.”
“I can tell you, having examined this issue in many jurisdictions, the best model is one that utilizes a single, cannabis dedicated regulator,” they said, responding to the idea that the existing medical marijuana program and a new adult-use one could instead be controlled by differing regulatory bodies. “This was the recommendation we made in Virginia based on an examination of best practices in several jurisdictions. And based on that experience, I can confirm that Pennsylvania’s program exhibits the challenges presented when a cannabis regulator is cast into an existing department.”
These Pennsylvania hearings have provided a broad overview of the experiences in out-of-state markets, rather than specific legislative proposals like a bipartisan measure introduced last year by Sens. Dan Laughlin (R) and Sharif Street (D).
Those senators also recently filed introduced a bill that would allow medical marijuana patients to cultivate their own plants for personal use. Street had attempted to get the reform enacted as an amendment to an omnibus bill this summer, but it did not advance.
Meanwhile, Street is behind another recent cannabis measure to provide state-level protections to banks and insurers that work with cannabis businesses.
In the interim, Lt. Gov. John Fetterman (D), who is running for U.S. Senate this year, said one of his key goals in his final year in office is to ensure that as many eligible people as possible submit applications to have the courts remove their cannabis records and restore opportunities to things like housing, student financial aid and employment through an expedited petition program.
Pennsylvania lawmakers could also take up more modest marijuana reform proposals like a bill filed late last year to expand the number of medical marijuana cultivators in the state, prioritizing small farms to break up what she characterized as a monopoly or large corporations that’s created supply problems.
Additionally, another pair of state lawmakers—Reps. Jake Wheatley (D) and Dan Frankel (D)—formally unveiled a legalization bill they’re proposing last year.
Philadelphia voters also approved a referendum on marijuana legalization in November that adds a section to the city charter saying that “the citizens of Philadelphia call upon the Pennsylvania General Assembly and the Governor to pass legislation that will decriminalize, regulate, and tax the use, and sale to adults aged 21 years or older, of cannabis for non-medical purposes.”
Wolf, the governor, said last year that marijuana legalization was a priority as he negotiated the annual budget with lawmakers. However, his formal spending request didn’t contain legislative language to actually accomplish the cannabis policy change.
The governor, who signed a medical cannabis expansion bill in June, has repeatedly called for legalization and pressured the Republican-controlled legislature to pursue the reform since coming out in favor of the policy in 2019. Shortly after he did that, a lawmaker filed a separate bill to legalize marijuana through a state-run model.
A survey from Franklin & Marshall College released last year found that 60 percent of Pennsylvania voters back adult-use legalization. That’s the highest level of support for the issue since the firm started polling people about it in 2006.
An attempt to provide protections for Pennsylvania medical marijuana patients from being charged with driving under the influence was derailed in the legislature last year, apparently due to pushback by the state police association.
Connecticut Lawmakers Discuss Bill To Fund Psilocybin And MDMA Therapy
Photo courtesy of Martin Alonso.
